Novel agent reactivates an immune call by LIF blockade

Promising new therapy with a dual mechanism of action to eliminate cancer stem cells and activate the immune system now in clinical development. Findings show a reactivation of the anti-cancer alarm system and draw parallels between embryogenesis and cancer. Combining LIF-neutralizing antibodies with immunotherapy promotes tumor regression, triggers immune memory, and increases survival in animal models.

Leave a Reply

Your email address will not be published. Required fields are marked *